# Torrent Pharmaceuticals Ltd (TORNTPHARM)
> Exchange: NSE | Sector: Pharma | ISIN: INE685A01028

## Price
Current Price: ₹4572.6
Day Change: +1.93%
52W High: ₹4469.05
52W Low: ₹2891.45
Market Cap: ₹1,49,446 Cr

## Valuation
P/E: 69.66
P/B: 17.66
EPS: ₹63.25
Book Value: ₹249.47
Dividend Yield: 0.79%

## Returns
1Y Return: 17.46%

## Profitability
ROE: 0%
ROCE: 28.63%
Debt/Equity: 0.33
Revenue Growth: 17.6%
Profit Growth: 26.1%
EBITDA Margin: 32.2%
Operating Margin: 26.7%

## About
Torrent Pharma is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Pharma — Formulations

## Business Model
Overview: Torrent Pharmaceuticals Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Core Business
- Other Segments
- Exports
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Business Segments:
- Core Business: 65% of tracked revenue, equal to ₹29,064 Cr. | 65% | ₹29,064 Cr
- Other Segments: 25% of tracked revenue, equal to ₹11,179 Cr. | 25% | ₹11,179 Cr
- Exports: 10% of tracked revenue, equal to ₹4,471 Cr. | 10% | ₹4,471 Cr
Recent Context:
- Announcement: Compliances-Reg.24(A)-Annual Secretarial Compliance
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- BSE Filing: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-25T14:00:11.436Z
Price History Updated: 2026-05-25T05:26:33.047Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:26:33.047Z
Quant Updated: 2026-05-25T05:26:33.047Z
Sentiment Updated: 2026-05-25T05:26:33.047Z
Financials Status: current
Financials Updated: 2026-05-18T02:33:30.321Z
Financials Last Attempt: 2026-05-18T02:33:30.321Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹4172 Cr
Operating Profit: ₹955 Cr (OPM 23%)
Net Profit: ₹664 Cr
Tax: ₹844 Cr

## Annual P&L History
Mar 2015: Rev ₹4172Cr | PAT ₹664Cr | OPM 23%
Mar 2016: Rev ₹4636Cr | PAT ₹751Cr | OPM 22%
Mar 2017: Rev ₹6687Cr | PAT ₹1733Cr | OPM 41%

## Balance Sheet (Mar 2015)
Total Assets: ₹5022 Cr
Total Liabilities: ₹5022 Cr
Borrowings: ₹1132 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Aman  Mehta, MD & Whole-Time Director
- Sudhir  Menon CA, CWA, Executive Director of Finance & CFO
- Ashish  Hajarnish M.Pharm, Executive Director of Operations
- Geena V. Malhotra, Chief Technology Officer
- Chintan M. Trivedi, Company Secretary & Compliance Officer

## Highlights
- Strong revenue growth of 17% CAGR over 5 years
- ROE of 15.0% indicates efficient capital allocation

## Concerns
- Debt-to-equity ratio needs monitoring amid expansion plans
- Promoter holding has seen slight decline in recent quarters

---
Source: rupiya.io/stocks/torntpharm
Disclaimer: For research and education only. Not investment advice.